Literature DB >> 25419061

Primary prostatic lymphoma in a young male with hiv infection.

Arjun Sivaraman1, Nagaraja Rao1, Suryakant Choubhey1, Mohan Adhyam1.   

Abstract

Primary lymphoma involving the prostate gland is rare. It accounts for 0.09 % of prostatic malignancies [1]. It commonly presents in the seventh decade with Lower Urinary Tract Symptoms (LUTS). Diffuse large B cell lymphoma is the common pathological variant [2]. Chemotherapy and radiotherapy are the common modalities of treatment and the overall prognosis is poor [2]. We present a 26 year old HIV infected patient - on anti-retroviral therapy who presented with acute renal failure and grossly enlarged prostate. Prostate biopsy with immuno-histochemistry confirmed the diagnosis of Peripheral T-cell lymphoma. He was treated with Adriamycin based chemotherapy and radiotherapy. We report this case in view of the rarity the tumor, younger age at presentation than that is available in literature and the pathological variant not reported in primary prostatic lymphoma.

Entities:  

Keywords:  Non-Hodgkin’s lymphoma; Prostate lymphoma; Prostate malignancy

Year:  2014        PMID: 25419061      PMCID: PMC4235862          DOI: 10.1007/s13193-014-0335-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  4 in total

1.  Lymphosarcoma of the prostate.

Authors:  L S KING; T R COX
Journal:  Am J Pathol       Date:  1951 Sep-Oct       Impact factor: 4.307

Review 2.  Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy.

Authors:  A Sarris; M Dimopoulos; W Pugh; F Cabanillas
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

3.  Malignant lymphoma involving the prostate: report of 62 cases.

Authors:  D G Bostwick; K A Iczkowski; M B Amin; G Discigil; B Osborne
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860

4.  Malignant lymphomas involving the prostate. A study of 13 cases.

Authors:  D G Bostwick; R B Mann
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.